cyrilzakka/clinical-trials huggingface dataset:
Mechanisms of Walking Recovery After Stroke

Subjects with stroke will have behavioral testing and brain imaging before and after a 4-week control period and a 4-week exercise intervention.

Subjects with stroke will have behavioral testing and brain imaging before and after a 4-week control period and a 4-week exercise intervention using high-intensity interval training.

Eligibility Criteria:
Inclusion Criteria:

* age 30-90 years
* unilateral stroke experienced \>6 months prior to enrollment in middle cerebral artery (MCA) territory without complete disruption of the putamen on the lesion side
* walking speed \<= 1.0 m/s on the 10 meter walk test
* able to walk 10m over ground with assistive devices as needed and no physical assistance

Exclusion Criteria:

* MRI incompatibility (e.g. metallic or electronic implants, severe claustrophobia)
* inability to perform mental imagery (time dependent motor imagery screening test \[TDMI\])
* evidence of significant arrhythmia or myocardial ischemia on treadmill ECG stress test, or significant baseline ECG abnormalities that would make an exercise ECG uninterpretable
* recent (\<3 months) cardiopulmonary hospitalization
* unable to communicate with investigators or correctly answer consent comprehension questions
* significant ataxia or neglect (score of 2 on NIH stroke scale item 7 or 11)
* severe lower extremity (LE) spasticity (Ashworth \>2)
* recent (\<3 months) illicit drug or alcohol abuse or significant mental illness
* major post-stroke depression (PHQ-9 ≥10) in the absence of medical management
* participating in physical therapy or another interventional research study;
* recent (\<3 months) paretic LE botulinum toxin injection
* concurrent progressive neurologic disorder or other major medical, orthopedic or peripheral vascular conditions that would limit improvement
* pregnancy
Exploratory Study to Determine Tissue Alterations of Advanced Hepatocellular Carcinoma Induced by Electromagnetic Waves of Low Energy Amplitude Modulated to Specific Frequencies During Imaging Study by MRI

This is an exploratory, national, single-center, open-label study, being conducted at the Institute of Education and Research of the Syrian-Lebanese Hospital in collaboration with the Radiology Institute, the Heart Institute of the Faculty of Medicine of São Paulo, Hospital São Paulo UNIFESP, and the Departments of Physics and Mathematics at the University of São Paulo in order to detect the presence of calcium flux change, tumor perfusion and electrical properties of tumor tissue when exposed to RF EMF AM by Cancer-frequency specific in patients with advanced HCC and correlate these findings with hemodynamic changes assessed by non-invasive hemodynamic measurements.

This study aims to demonstrate the presence of three mechanisms (hypothesis) that could be involved in the hemodynamic changes and the specific antitumor effect induced by exposure to RF EMF AM cancer-specific frequency. This study is not intended to study a therapeutic or diagnostic procedure. For this reason, will not be considered evolutionary clinical data during and after the intervention of the study.


Eligibility Criteria:
Inclusion Criteria:

All individuals selected for these studies should be in accordance with the following inclusion criteria:

* Patients must have a diagnosis of HCC.
* Presence of the primary or metastatic tumor at the time of the procedure, at least one (1) measurable lesion by RECIST criteria modified located in the hepatic parenchyma and size\> 2 cm.
* Patients with AFP\> 400 ng / ml and image feature not need histopathological confirmation. But in patients with active B virus serology, the value of AFP should be greater than 4000 ng / ml. The remaining patients should be histological confirmation of HCC.
* Patients may be in observation or presence of systemic or intra-hepatic treatment.
* Minimum age 18 years.
* be subjected to MRI study without need for sedation.

Exclusion Criteria:

* Individuals selected for this study will be excluded if they are in accordance with the following exclusion criteria:

  * can not suspend anti-hypertensive drugs or beta blockers for at least 48 hours or be pacemaker carriers or other implantable device.
  * Any restriction known to carry out study of magnetic resonance imaging.
  * menstrual delay, pregnant or breastfeeding.
  * Presence of metal artifacts or implants that can alter the reading of the magnetic signal or heat or move during the MRI procedure.
  * Prior allergic Event Knowledge gadolinium or manganese chloride solution.
Manual Hyperinflation and Physical Therapy Program on Lung Recruitment Mechanically Ventilated Pediatric Patients

The purpose of this study is to investigate the immediate combined effects of Manual Hyperinflation and standard Physical therapy program on lung recruitment and secretion mass in mechanically ventilated pediatric patients aged between 10-15 years 'old

In developing countries, lower respiratory tract infection is a major cause of death in children, with severely ill patients being admitted to the critical-care unit. While physical therapists commonly use the manual hyperinflation (MHI) technique for secretion mass clearance in critical-care patients, its efficacy has not been determined in pediatric patients.

Manual hyperinflation is a frequently maneuver used in critically ill intubated and mechanically ventilated patients. With MHI, patients are disconnected from the mechanical ventilator after which their lungs are temporarily ventilated with a manual ventilation bag. so, by applying a larger than normal volume at a low inspiratory pause and expiration with a high expiratory flow, MHI is suggested to mimic a normal cough.

Propagation of airway secretions from the smaller toward the larger airways, then allows for easy removed of airway secretions with the airway suction. finally, MHI could prevent airway plugging and even promote alveolar recruitment. so the aim of the study is to enhance lung recruitment using MHI combined with standard Physical therapy program

Eligibility Criteria:
Inclusion Criteria:

* The patients will be aged 10-15 years,
* receiving mechanical ventilation via an endotracheal tube for at least 24 h
* presenting with vital signs in the normal range.
* All patients are suffering from lower respiratory tract infection like pneumonia, bronchitis and acute exacerbation of bronchiectasis

Exclusion Criteria:

* Patients with history of thoracic surgery
* Patients with pneumothorax or acute respiratory distress syndrome
* Patients with severe acute head injury
* Patients use inotropes and vasopressors drugs
* Patients with severe Broncho pleural fistula, rib fracture, emphysema bullae, lung abscess, patients with history of preterm birth or heart disease.
* Patients who requiring mechanical ventilation with a peak inspiratory pressure (PIP)
Long Term Study of Genotropin (Somatropin) for Short Children Born Small for Gestational Age (SGA)

To assess the long-term safety of Genotropin(somatropin) on Small for Gestational Age (SGA) without epiphyseal closing.


Eligibility Criteria:
Inclusion Criteria:

Children with short stature due to SGA who received treatment in the study GENASG-0021-002.

Exclusion Criteria:

* Children who have any chronic disease requiring treatment with steroid hormone that may affect growth promotion including estrogen, androgen, anabolic hormone, and corticosteroids (except those for external use), and have received the treatment.
* Children who have received radiotherapy or chemotherapy.
* Children who have serious cardiac disease, renal disease, or hepatic disease.
* Children who have diabetes mellitus with a manifestation of abnormal glucose metabolism.
* Children who have serious chronic disease.
* Children who have malignant tumor.
* Children who are allergic to m-cresol.
Making Football Safer for Women: Implementing an Injury Prevention Program

The aim of this study is to determine how we can best support coaches to implement an injury prevention (IP) program (Prep-to-Play) in female community Australian Football. We will recruit at least 140 female community football teams from 15 different football leagues in Victoria, Australia. Teams will be competing in U16, U17, U18, U19 or open womens competitions. We will train and support coaches to implement the IP program and evaluate the effects of the IP program on injuries across two football seasons.

Primary Aim: To compare the impact of supported and unsupported implementation strategies on the use of an IP program (Prep-to-Play) in female community Australian Football.

Secondary aims are to:

1. Evaluate the effects of supported implementation of Prep-to-Play on injury risk reduction.
2. Identify barriers and enablers to sustainability of the Prep-to-Play implementation model, and develop clear recommendations for a future, sustainable national roll out of Prep-to-Play.
3. Evaluate the cost-effectiveness of Prep-to-Play.

Primary hypothesis

The primary hypothesis is that supported implementation will result in increased use of Prep-to-Play in female community Australian Football compared to unsupported implementation.

Secondary hypotheses

The secondary hypotheses are that the supported implementation of Prep-to-Play will:

* result in a reduction of anterior cruciate ligament (ACL) injuries in females participating in community Australian Football;
* result in a reduction of other musculoskeletal injuries and concussion among females participating in community Australian Football;
* be more cost-effective than the unsupported implementation.

Eligibility Criteria:
Inclusion Criteria

* Coach consents to be trained and to implement Prep-to-Play
* Team includes players aged 13 years and above registered to play community football
* The team trains at least once per week in addition to match-play
* Coach has at least Level I coach accreditation (or enrolled to be accredited in 2021)

Exclusion Criteria:

* Inability to understand written English
* Players aged less than 13 years
A Comparison of Two Brief Interventions for People with Chronic Low Back Pain

The goal is to undertake a Decentralized Randomized Pilot Feasibility study to inform the methods for a definitive Randomized Controlled Trial (RCT) (including recruitment success, participant experience, intervention delivery, safety, outcome measurement and sample size estimation). The main question is if the methods used are feasible for an adequately powered future RCT. Participants will be randomly allocated to receive either: Intervention - OldPain2Go® treatment or Placebo Control - Jacobson's progressive relaxation

The project is a virtual Randomized Control Trial and the independent variable is OldPain2Go® a novel brief intervention for people with chronic low back pain. The investigators aim to answer the research question: Is OldPain2Go® an effective intervention for pain and function in people with chronic low back pain - when applied in an adequately powered RCT comparing OldPain2Go® with placebo? The Intervention arm participants will receive OldPain2Go® and the Control arm participants will receive Jacobson's progressive relaxation, as a placebo. The Control (placebo) is a commonly used element of treatment, for a wide range of conditions, but is never applied only once (or twice) as a treatment.

Eligibility Criteria:
Inclusion Criteria:

* Currently suffering from persistent, non-specific, low back pain of six or more months duration
* No known tissue damage, structural abnormality, or pathology causing persistent low back pain
* Aged over 18 years
* Person's for whom Oldpain2go® is indicated as a treatment option, after the standard clinical screening process for the Oldpain2go® treatment
* Has access to digital communication device able to host encrypted secure on-line meetings.

Exclusion Criteria:

* Any Red Flags,
* Any causative (or potentially causative) structural abnormality, or pathology detected or suspected
* Any concurrent pathology, or condition that would render them unsuitable for on-line virtual assessment and Physiotherapy treatment
* Lack of (or any reason to doubt presence of) Mental Capacity to give Informed Consent
Pilot Program to Improve Statin Adherence and Lower Cholesterol in Older Adults

The purpose of this study is to pilot test a behavioral medication adherence (MA) intervention compared to control condition in older adults with low adherence to medication for hypercholesterolemia.

This study will answer the following primary research question:

1. What is the estimated effect size of a behavioral MA intervention on MA rates in older adults who are poorly adherent to statin medications?

   The study will also explore the following secondary research questions:
2. What is the estimated effect size of a behavioral MA intervention on low-density lipoprotein cholesterol (LDL-C) levels in older adults?
3. What is the estimated effect size of a behavioral MA intervention on high-density lipoprotein cholesterol (HDL-C) levels in older adults?
4. What is the feasibility of successfully testing this intervention protocol in a population of older adults with low adherence to statin medications?

Eligibility Criteria:
Inclusion Criteria:

* Age 60 or older at the time of study entry,
* Take a once-daily prescription statin medication for ≥ 6 months with no changes to statin prescription for at least 30 days prior to study entry,
* A score of ≤ 9 on the Short Blessed Test,
* Participants must self-administer his or her own medications without prompts from any other person or device.
* Baseline medication adherence rate of ≤ 90%.
* Participants agree to complete all study contacts and measurements, including the use of a special medication bottle with a Medication Event Monitoring System (MEMS) cap for the duration of the study.
* Able to open and close MEMS caps.

Exclusion Criteria:

* Participant's medications are managed by someone other than the participant
* Participant is unable or unwilling to use MEMS caps.
Discontinuation of Antiviral Therapy as a Strategy to Cure Hepatitis B

Cirrhosis or cancer of the liver caused by hepatitis B virus (HBV) are major global health problems. Chronic HBV infection has become more common in Sweden with immigration. The risk of cancer and the availability of effective antivirals has led to more and more people receiving long-term treatment with antiviral drugs. The disadvantages of this treatment are that it does not have a defined duration and that it very rarely leads to the cure. Several published studies suggest that a large proportion of patients who discontinue antiviral therapy after at least three years may achieve lasting cure of the infection or at least do not need to resume treatment. The mechanism of this effect is not known, but it is thought to be due to the fact that the immune response, which is activated when the amount of virus increases after the end of treatment, becomes more effective in eradicating infected liver cells than it was before starting treatment. As a consequence of these findings updated guidelines for treatment of hepatitis B state that for patients that have received nucleoside analogue treatment for \> 3 years, discontinuation is an accepted therapeutic alternative.

The purpose of the planned study is to investigate the results of discontinued treatment, in terms of clinical outcome as well as immunological and virological mechanisms. The aim is to include 120 patients at four regional infectious diseases clinics (in Gothenburg, Borås, Skövde and Trollhättan), of which 90 will be randomized to discontinue and 30 to continue antiviral treatment. Blood samples will be taken regularly to monitor the outcome and for detailed studies of viral antigens and nucleic acid in the blood and for specific analyzes of the cells of the immune system. The goal is to understand why the discontinued treatment in some patients activates an effective immune response and how such an effect can be predicted even before or early after the treatment is stopped.


Eligibility Criteria:
Inclusion Criteria:

* Nucleoside analogue treatment for HBeAg-negative chronic hepatitis B for at least 36 months.

Exclusion Criteria:

* Liver cirrhosis or liver cancer.
* Co-infection with HCV, HDV or HIV.
* Inability to understand study information and give informed consent
MCAT With HA and sCTG Compared With sCTG Alone for Treatment of Multiple Gingival Recession: Clinical Trial

Microsurgical tunneling flap procedures using connective tissue grafts (CTG) are predictable for treating teeth with gingival recessions. Cross-linked hyaluronic acid can be used in conjunction with subepithelial palatal connective tissue grafts to improve postsurgical results. The aim of this study is to evaluate clinically the use of tunnel technique with CTG and cross-linked hyaluronic acid in addition to CTG alone for the treatment of multiple gingival recessions.

The treatment of multiple adjacent recession appears to be challenging for the clinician due to large surgical field, variation in teeth position in the dental arch (prominent roots), variation in recession size, thin phenotype and insufficient keratinized tissue in many teeth. Surgical treatment of all multiple recession in one dental arch during one session appears to be optimum. Surgical treatment time is longer, however patient doesn't need to undergo multiple surgeries, pharmacological therapies and postsurgical instructions. Esthetic concern seems to be one of the most common complaints from patients. Among utilized surgical techniques tunneling flap procedures using connective tissue grafts (CTG) with or without biologics such as an enamel matrix derivative (EMD) or hyaluronic acid (HA) provided the most successful outcomes for the treatment. Cross-linked hyaluronic acid can be used in conjunction with subepithelial palatal connective tissue grafts to improve postsurgical results and improving healing process. The aim of this study is to evaluate clinically the use of tunnel technique with CTG and cross-linked hyaluronic acid in addition to CTG alone for the treatment of multiple gingival recessions.

Eligibility Criteria:
Inclusion Criteria:

* Age ≥ 18 years
* Bilateral multiple gingival recessions in homologous teeth

Exclusion Criteria:

* Full-mouth plaque index ≥ 20% (Ainamo \& Bay 1975)
* Full-mouth sulcus bleeding index ≥ 15% (Mühlemann \& Son 1971)
* Smoking
* Systemic diseases with compromised healing potential of infectious diseases
* Drugs affecting periodontal health / healing
* Pregnant and lactating females
* Previous periodontal surgery in the area
Aquatic and Land Exercises in Chronic Low Back Pain

Aquatic and Land Exercises on Chronic Low Back Pain

The Effect of Aquatic and Land Exercises on Pain, Health Related Quality of Life, Kinesiophobia and Disability in Chronic Low Back Pain

Eligibility Criteria:
Inclusion Criteria:

* patients had to be diagnosed with clinical examination and radiological findings of low back pain from at least 6 months.

Exclusion Criteria:

* acute pain
Study of the Efficacy and Safety of MK-0476 in Japanese Pediatric Participants With Seasonal Allergic Rhinitis (MK-0476-519)

This study will evaluate the efficacy and safety of montelukast (MK-0476) in the treatment of Japanese pediatric participants with seasonal allergic rhinitis (SAR). The primary hypothesis of this study is that montelukast is superior to placebo in the treatment of nasal symptoms in SAR.


Eligibility Criteria:
Inclusion Criteria:

* Weight: ≥ 25 kg
* Height: ≥ 125 cm
* Able to record symptoms in a diary
* Has had allergic rhinitis symptoms \[Japanese Cedar (JC) pollinosis\]
* Tested positive for JC pollen specific immunoglobulin E (IgE) antibody assay

Exclusion Criteria:

* Has nasal findings that would interfere with evaluating nasal congestion symptoms
* Past or present medical history of bronchial asthma
* Medical history of allergies except allergic rhinitis and has possibility of dramatically worsening of these symptoms induced by JC pollen exposure
Molecular Evaluation of AML Patients After Stem Cell Transplant to Understand Relapse Events

Prospective determination of the clinical utility of measurable residual disease (MRD) testing for relapse and survival of patients with acute myeloid leukemia (AML) undergoing allogeneic hematopoietic cell transplantation (alloHCT).

This is a multi-center non-randomized prospective study designed to establish a national framework for introducing measurable residual disease testing into the clinical care of AML patients undergoing allogeneic transplantation.

Enrollment is expected to occur over a 4-year period, with an additional 3 years of follow-up. Subject participation this study will be approximately 3 years. Up to 1,000 subjects will be enrolled.

Subjects will be asked to provide blood samples at months 1-6, 9, 12, 15, and 18 post-transplant, and archived specimens from time of AML diagnosis and any bone marrow samples collected for clinical purposes will be requested for research testing. Additional blood and marrow samples will be requested at relapse (if applicable).

Eligibility Criteria:
Inclusion Criteria:

1. Provision of signed and dated informed consent form
2. Stated willingness to comply with all study procedures and availability for the duration of the study
3. Aged at least 18 years old at time of consent
4. Diagnosed with AML, in complete remission

   1. Complete remission (CR) definition per local institutional criteria
   2. CR with incomplete hematologic recovery (CRi) is not an exclusion criterion
   3. MRD positivity is not an exclusion criterion
5. Undergoing alloHCT
6. Has a diagnostic AML specimen available

Exclusion Criteria:

1. Diagnosis of acute promyelocytic leukemia
2. Prior alloHCT
Pilot HPV Vaccination in Chinese American Community

This study provides a pioneer model in increasing knowledge of HPV vaccination among Chinese American families through culturally tailored interventions, and eventually increase the HPV vaccine uptake among Chinese American adolescents.


Eligibility Criteria:
Inclusion Criteria:

1. Self-identified Chinese Parents or legal guardian with children aged 11-18 years old;
2. The children have not received any does of HPV vaccination

Exclusion Criteria:

-
Suturable DuraGen™ PMCF Study

The primary goal of this study is to retrospectively collect data on the safety and efficacy of Suturable DuraGen™.

This is a multicenter, non-randomized, non-interventional, retrospective Post-Market Clinical Follow-up (PMCF) study to evaluate the occurrence of post-operative cerebrospinal fluid (CSF) leaks within 30 days (and up to 90 days) after use of Suturable DuraGen™ for a supratentorial, infratentorial, or spinal procedure.

Eligibility Criteria:
Inclusion Criteria:

1. Subject is between 18 and 80 years of age
2. Subject has undergone either a supratentorial, an infratentorial, or a spinal procedure with the use of Suturable DuraGen™ prior to trial initiation
3. Availability of post-operative assessment results.

Exclusion Criteria:

1. There are no exclusionary criteria for this study population